Market Place
Sourcing Support
Allakos axes program, lays off 75% of staff after phase 1 flop
28 Jan 2025 //
FIERCE BIOTECH
Allakos Announces AK006 Trial Results & Company Restructuring
27 Jan 2025 //
GLOBENEWSWIRE
Allakos Reports Q3 2024 Financials & Provides Business Update
06 Nov 2024 //
GLOBENEWSWIRE
Allakos Announces Ph 1 Trial Results of Subcutaneous AK006
10 Oct 2024 //
GLOBENEWSWIRE
Allakos Provides Q2 2024 Financial Results And Business Update
07 Aug 2024 //
GLOBENEWSWIRE
Allakos Announces Positive Phase 1 Trial Results of AK006 in Healthy Volunteers
25 Jun 2024 //
GLOBENEWSWIRE
Allakos: First Patient Dosed In AK006 Phase 1 Chronic Urticaria Trial
28 May 2024 //
GLOBENEWSWIRE
Allakos Q1 2024 Results And Business Update
09 May 2024 //
GLOBENEWSWIRE
Allakos Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
Allakos Presents Data Highlighting Inhibition of MRGPRX2-Mediated Activation
26 Feb 2024 //
GLOBENEWSWIRE
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
12 Feb 2024 //
GLOBENEWSWIRE
Allakos halves workforce, drops lead inflammatory program
17 Jan 2024 //
ENDPTS
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis
16 Jan 2024 //
PRESS RELEASE
Allakos Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Allakos Appoints Neil Graham to its Board of Directors
30 Aug 2023 //
GLOBENEWSWIRE
Allakos Provides Business Update & Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
02 Aug 2023 //
GLOBENEWSWIRE
Allakos Presents Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab
12 Jun 2023 //
GLOBENEWSWIRE
Allakos Announces Upcoming Presentation on Lirentelimab and AK006
05 Jun 2023 //
GLOBENEWSWIRE
Why Allakos Stock Skyrocketed Nearly 9% Higher Today
13 May 2023 //
FOOL
Allakos Provides Business Update and Reports1Q 2023 FYR
09 May 2023 //
GLOBENEWSWIRE
Allakos Reports Fourth Quarter and Full Year 2022 Financial Results
06 Mar 2023 //
GLOBENEWSWIRE
Allakos Announces Publication of AK006 Mechanism of Action Manuscript
29 Nov 2022 //
GLOBENEWSWIRE
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist,at (SITC)
10 Nov 2022 //
GLOBENEWSWIRE
Allakos Provides Business Update and Reports 3Q 2022 Financial Results
07 Nov 2022 //
GLOBENEWSWIRE
Allakos Announces Pricing of $150 M Underwritten Offering of Common Stock
19 Sep 2022 //
PRESS RELEASE
With hit-and-miss data, Allakos goes the public offering route in $150M ask
19 Sep 2022 //
ENDPTS
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
19 Sep 2022 //
APNEWS
Allakos Announces Initiation of Ph2b Trial of Subcutaneous Lirentelimab
12 Sep 2022 //
GLOBENEWSWIRE
Allakos’ failed phase 3 EoDyssey sinks gastrointestinal program
10 Sep 2022 //
FIERCEBIOTECH
Allakos Announces PIII Data from the EoDyssey Study in Patients
09 Sep 2022 //
GLOBENEWSWIRE
Allakos Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
25 Jul 2022 //
GLOBENEWSWIRE
Allakos Provides Business Update and Reports Q1 2022 Financial Results
06 May 2022 //
GLOBENEWSWIRE
Allakos Provides Business Update and Q4 and Full Year 2021 Financial Results
01 Mar 2022 //
GLOBENEWSWIRE
Allakos drops a pair of duds on patient-reported symptom relief for GI disease
23 Dec 2021 //
ENDPTS
Allakos Announces Topline ENIGMA 2 Study and KRYPTOS Study
21 Dec 2021 //
GLOBENEWSWIRE
Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence
25 Oct 2021 //
GLOBENEWSWIRE
Allakos Announces Multiple Presentations Related to Eosinophil & Mast Cell
23 Oct 2021 //
GLOBENEWSWIRE
Allakos Completes Patient Enrollment in Clinical Trials of Lirentelimab
07 Jun 2021 //
GLOBENEWSWIRE
Allakos Announces Multiple Presentations Related to Eosinophil and Mast
30 Mar 2021 //
GLOBENEWSWIRE
Allakos Announces Presentation from its Eosinophilic GST Diseases Program
02 Nov 2020 //
PRESS RELEASE
Allakos Announces Results from a Phase 1 Study of Subcutaneously Lirentelimab
26 Oct 2020 //
GLOBENEWSWIRE
Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis
26 Oct 2020 //
GLOBENEWSWIRE
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab
21 Oct 2020 //
PIPELINEREVIEW
Allakos Initiates Patient Recruitment for AK002 Registrational Studies
03 Jun 2020 //
GLOBENEWSWIRE
Allakos Announces Multiple Presentations Related to Eosinophil
21 May 2020 //
GLOBENEWSWIRE
Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001
11 May 2020 //
GLOBENEWSWIRE
Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic
11 May 2020 //
GLOBENEWSWIRE
Allakos Announces Interim Results from an Open-Label Extension of Antolimab
04 May 2020 //
GLOBENEWSWIRE
Allakos Announces Positive Phase 1 Results with Antolimab (AK002)
24 Mar 2020 //
GLOBENEWSWIRE
